Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.59 |
| ▸ | CTSD | P07339 | 3/20 | 0.59 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904429 | 1.00 | BACE1 (0.59) | BACE1CTSDBACE2BCHESLC6A11 | |
| SCHEMBL5377462 | 1.00 | BACE1 (0.59) | BACE1CTSDBACE2BCHESLC6A11 | |
| SCHEMBL5379684 | 0.88 | BACE1 (0.55) | BACE1CTSDBACE2BCHESLC6A11 | |
| SCHEMBL3915004 | 0.88 | BACE1 (0.55) | BACE1CTSDBACE2BCHESLC6A11 | |
| SCHEMBL5379678 | 0.88 | BACE1 (0.55) | BACE1CTSDBACE2BCHESLC6A11 | |
| SCHEMBL7608787 | 0.88 | BACE1 (0.57) | BACE1BCHESLC6A11 | |
| SCHEMBL6893071 | 0.88 | BACE1 (0.57) | BACE1BCHESLC6A11 | |
| SCHEMBL7608795 | 0.88 | BACE1 (0.57) | BACE1BCHESLC6A11 | |
| SCHEMBL7608330 | 0.86 | BACE1 (0.54) | BACE1CTSDBACE2 | |
| SCHEMBL7608338 | 0.86 | BACE1 (0.54) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | BACE1 7/4885CTSD 1351/4885BACE2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.